← Back

Tibet Cheezheng Tibetan Medicine Co Ltd

Tibet Cheezheng Tibetan Medicine Co., Ltd. researches, develops, produces, and sells Tibetan medicines in China and internationally. Its products include plasters, topical and oral Tibetan and traditional Chinese medicine products, external analgesics, and ointments. These products are used in orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculoskeletal, nervous system, digestive, urinary, and cerebrovascular areas. Founded in 1995 and headquartered in Nyingchi, China, the company is a subsidiary of Gansu Qizheng Industry Group Co., Ltd.

Country
Price · split & dividend adjusted
News & notes moving 002287.CS
China
002287.CS▼3

Cheezheng Tibetan Medicine Releases 2026 Interim Report with Net Profit of 371 Million Yuan

Cheezheng Tibetan Medicine released its 2026 interim report, with net profit attributable to the parent company of 371 million yuan. The company's total operating revenue was 978 million yuan, down 16.77 percent from the same period last year. Net cash inflow from operating activities was 239 million yuan, down 51.25 percent year on year. The company's latest gross margin was 82.08 percent, latest return on equity was 7.28 percent, and diluted earnings per share was 0.66 yuan.
Tibet Cheezhen… ▼
002287.CS · Capital · Negative Revenue and operating cash flow declined significantly year over year, though net profit was reported.
Read original ↗
Jiemian·44dRead more →
China
002287.CS

Qizheng Tibetan Medicine's first-half net profit attributable to parent was 371 million yuan, up 3.6% year on year

Qizheng Tibetan Medicine released its 2026 interim report. Net profit attributable to the parent in the first half was 371 million yuan, up 3.6% year on year. Operating revenue was 978 million yuan, down 16.8% year on year. Net profit attributable to the parent excluding non-recurring items was 300 million yuan, up 3.6% year on year. Net operating cash flow was 239 million yuan, down 51.3% year on year. In the second quarter, operating revenue was 573 million yuan, down 25.8% year on year, and net profit attributable to the parent was 276 million yuan, down 2.3% year on year. The company said industry development conditions are relatively positive, with industrial policies and regulatory details from multiple ministries being rolled out one after another, providing support for the transformation and development of the traditional Chinese medicine industry. The company continues to maintain its leading position in the Tibetan medicine market.
Tibet Cheezhen…
002287.CS · Capital · Neutral Net profit up 3.6% but revenue down 16.8% and cash flow down 51.3%, mixed results.
Read original ↗
财中社·45dRead more →
China
002287.CS▲

Qizheng Tibetan Medicine's first-half non-GAAP net profit rises 3.59%; interim dividend of 2.3 yuan per 10 shares proposed

Qizheng Tibetan Medicine disclosed its 2026 semi-annual report on the evening of August 21. In the first half, it achieved operating revenue of 978 million yuan, and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of 300 million yuan, up 3.59% year on year. It also plans to distribute a cash dividend of 2.3 yuan per 10 shares, tax included, to all shareholders. Operating profit for the same period was 416 million yuan, and net profit attributable to shareholders of the listed company was 371 million yuan. Qizheng Tibetan Medicine is a leading modern Tibetan medicine enterprise. Its core product, Xiaotong Plaster, ranks first among external-use plasters in the skeletal and muscular system category of Chinese patent medicines, and its share of the Tibetan medicine market exceeds 50%.
Tibet Cheezhen… ▲
002287.CS · Capital · Positive First-half net profit up 3.59% and interim dividend proposed.
Read original ↗
上海证券报·45dRead more →
© 2026 MarketDXAsset